Bisphosphonate treatment in inaccessible osteoid osteomas: An alternative therapeutic approach.
Bisphosphonate
Osteoid osteoma
Treatment
Zoledronic acid
Journal
Joint bone spine
ISSN: 1778-7254
Titre abrégé: Joint Bone Spine
Pays: France
ID NLM: 100938016
Informations de publication
Date de publication:
Dec 2023
Dec 2023
Historique:
received:
14
04
2023
revised:
28
04
2023
accepted:
08
05
2023
medline:
4
12
2023
pubmed:
19
5
2023
entrez:
18
5
2023
Statut:
ppublish
Résumé
Osteoid osteoma is a benign osteogenic tumour traditionally treated by surgical excision or percutaneous CT-guided procedures. We describe three cases of osteoid osteomas of which the locations were difficult to access, or for which the procedure was potentially unsafe, involving treatment with zoledronic acid infusions. We report here three male 28-to-31-year-old patients with no medical history who had osteoid osteomas located at the second cervical vertebra, the femoral head, and the third lumbar vertebra respectively. These lesions were responsible for inflammatory pain requiring daily treatment with acetylsalicylic acid. Given the impairment risk, all of the lesions were ineligible for surgical or percutaneous treatment. Patients were successfully treated by 3 to 6 monthly zoledronic acid infusions. All patients experienced complete relief of their symptoms allowing aspirin discontinuation, without any side effects. In the first two cases, CT and MRI control showed nidus mineralization and bone marrow oedema regression, correlating with the pain decrease. After 5years of follow-up, there had been no recurrence of the symptoms. In these patients, monthly 4mg zoledronic acid infusions have been safe and effective in the treatment of inaccessible osteoid osteomas.
Identifiants
pubmed: 37201577
pii: S1297-319X(23)00068-4
doi: 10.1016/j.jbspin.2023.105589
pii:
doi:
Substances chimiques
Diphosphonates
0
Zoledronic Acid
6XC1PAD3KF
Types de publication
Case Reports
Langues
eng
Sous-ensembles de citation
IM
Pagination
105589Informations de copyright
Copyright © 2023 Société française de rhumatologie. Published by Elsevier Masson SAS. All rights reserved.